# Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

> **NCT05841134** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 25 (estimated)

## Conditions studied

- MSI-H Colorectal Cancer
- Tislelizumab
- Oxaliplatin
- Capecitabine

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05841134
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05841134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05841134, "Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05841134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*